ALPACA Trial – Lepodisiran Significantly Reduces Lipoprotein(a) in Phase II Trial
Key Points Elevated lipoprotein(a) is associated with incident atherosclerotic cardiovascular disease and…
TRILUMINATE– Transcatheter edge-to-edge repair reduces TR severity and HF Hospitalizations
Key Points The TRILUMINATE Pivotal trial previously reported that transcatheter edge-to-edge repair…
PURSUIT Trial – Dose Dependent Reduction in LDL-C with AZD0780, Oral PCSK9 inhibitor
Key Points The majority of ASCVD patients fail to achieve guideline endorsed…